貨號(hào)：GS40497

Olokizumab is a humanized monoclonal antibody that specifically targets interleukin?6 (IL?6), a key pro?inflammatory cytokine. Unlike some other anti?IL?6 therapies that block the IL?6 receptor (e.g., tocilizumab), olokizumab binds directly to the IL?6 cytokine itself, preventing it from interacting with both the membrane?bound and soluble forms of the IL?6 receptor (IL?6R). This inhibition blocks downstream JAK/STAT and MAPK signaling, reducing systemic and local inflammation. It is approved in Russia for the treatment of moderate?to?severe rheumatoid arthritis (RA) in adults who have had an inadequate response to disease?modifying anti?rheumatic drugs (DMARDs). It is administered via subcutaneous injection.